ArticleFrontiers in pharmacology2022

The Treatment With the SGLT2 Inhibitor Empagliflozin Modifies the Hepatic Metabolome of Male Zucker Diabetic Fatty Rats Towards a Protective Profile.

Alana Aragón-Herrera et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.